Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Orexigen Therapeutics, Inc. (OREXQ)
|
Add to portfolio |
|
|
|
| Price: |
$0.22
| | Metrics |
| OS: |
16.6
|
M
| |
-152
|
% ROE
|
| Market cap: |
$3.7
|
M
| |
-1129
|
% ROIC
|
|
Net cash:
|
$191
|
M
| |
$11.53
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($151)
|
M
| |
|
|
|
EBIT
|
($159)
|
M
| |
|
|
| EPS |
($9.71)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 |
| Revenues | 33.7 | 24.5 | 55.5 | 3.4 | 3.4 | 4.4 | 1.2 | 0.1 |
| Revenue growth | 37.8% | -55.9% | 1519.6% | 0.0% | -22.1% | 257.4% | 1298.9% | 0.0% |
| Cost of goods sold | 8.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 25.7 | 24.5 | 55.5 | 3.4 | 3.4 | 4.4 | 1.2 | 0.1 |
| Gross margin | 76.3% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | 118.6 | 43.8 | 28.6 | | | | | |
| Research and development | 38.0 | 40.8 | 57.4 | 56.7 | 73.7 | 12.8 | 28.1 | 47.4 |
| General and administrative | | | | 23.9 | 20.0 | 19.5 | 24.5 | 18.2 |
| EBITA | -50.7 | -60.1 | -30.5 | -77.2 | -90.2 | -27.9 | -51.4 | -65.5 |
| EBITA margin | -150.3% | -245.5% | -55.0% | -2252.0% | -2632.4% | -633.8% | -4175.1% | -74465.9% |
| Amortization of intangibles | 3.3 | | | | | | | |
| EBIT | -54.0 | -60.1 | -30.5 | -77.2 | -90.2 | -27.9 | -51.4 | -65.5 |
| EBIT margin | -160.1% | -245.5% | -55.0% | -2252.0% | -2632.4% | -633.8% | -4175.1% | -74465.9% |
| Pre-tax income | -24.4 | -67.3 | -37.5 | -77.7 | -90.1 | -28.1 | -51.9 | -66.6 |
| Income taxes | 0.1 | 1.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -24.5 | -68.7 | -37.5 | -77.7 | -90.1 | -28.1 | -51.9 | -66.6 |
| Net margin | -72.8% | -280.8% | -67.6% | -2265.8% | -2628.2% | -637.8% | -4217.3% | -75638.6% |
| |
| Diluted EPS | ($1.68) | ($5.24) | ($3.17) | ($0.80) | ($1.27) | ($0.58) | ($1.10) | ($1.67) |
| Shares outstanding (diluted) | 14.6 | 13.1 | 11.8 | 96.5 | 70.7 | 48.3 | 47.4 | 39.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|